68Ga-PSMA-HBED-CC PET/CT显像中偶然检出甲状腺功能减退
Incidental Detection of Hypothyroidism on 68Ga-PSMA-HBED-CC PET/CT Imaging.
PubMed 文献 · Clin Nucl Med · 2020-01-01
本文报告一例新诊断前列腺癌患者,在68Ga-PSMA-HBED-CC PET/CT显像中显示甲状腺两叶弥漫性68Ga-PSMA摄取,经进一步临床和生化检查确诊为甲状腺功能减退。文章提示68Ga-PSMA PET/CT广泛使用后,良性病变亦可出现非前列腺摄取。
要点
- 68Ga-PSMA PET/CT除前列腺癌病灶外,可见良性病变的非前列腺摄取。
- 本例甲状腺两叶弥漫性68Ga-PSMA摄取,经临床和生化检查确诊为甲状腺功能减退。
- 前列腺癌患者行68Ga-PSMA PET/CT时,甲状腺弥漫性摄取可能提示甲状腺功能减退。
核心结论
- 新诊断前列腺癌患者68Ga-PSMA PET/CT示甲状腺两叶弥漫性68Ga-PSMA表达,经临床和生化检查确诊为甲状腺功能减退。
研究设计与样本
- 个案报告:一例新诊断前列腺癌患者行68Ga-PSMA-HBED-CC PET/CT显像。
主要发现
- 68Ga-PSMA PET/CT显示甲状腺两叶弥漫性68Ga-PSMA摄取。
- 进一步临床和生化检查确立甲状腺功能减退诊断。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ga-labeled prostate-specific membrane antigen (PSMA) ligand PET/CT is a rapidly evolving imaging modality for prostate cancer. However, with the widespread use of Ga-PSMA PET/CT, various reports of nonprostatic uptake of Ga-PSMA in both benign and malignant lesions have also appeared. We report a recently diagnosed case of prostate cancer demonstrating diffuse Ga-PSMA expression in both the lobes of thyroid gland, which on further clinical and biochemical investigations was established as hypothyroidism.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Sood A, Vadi SK, Kumar R, et al. Incidental Detection of Hypothyroidism on 68Ga-PSMA-HBED-CC PET/CT Imaging. Clin Nucl Med. 2020. PMID: 32108699. doi:10.1097/RLU.0000000000002965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。